ÁLVAREZ-ROMÁN, M. T.; CUERVO-ARANGO, I.; PÉREZ-SANTAMARINA, R.; POVEDA, J. L.; ROMERO, J. A.; SANTAMARÍA, A.; TRILLO-MATA, J. L.; TORT, M.; BADIA, X. Determining the value contribution of emicizumab (Hemlibra®) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis. Global and Regional Health Technology Assessment, [S. l.], v. 6, n. 1, 2019. DOI: 10.33393/grhta.2019.452. Disponível em: https://journals.aboutscience.eu/index.php/grhta/article/view/452. Acesso em: 3 jul. 2024.